31 results about "Tissue specific gene" patented technology

A method of ascertaining the bio-safety of an agent is disclosed. The method comprises:(a) contacting the agent with differentiating human pluripotent stem cells;(b) analyzing a level of gene expression of a plurality of genes in the differentiating human pluripotent stem cells, wherein the agent is qualified as being safe if at least one of the following qualification parameters are fulfilled:(i) the agent causes a difference in the level of gene expression below a predetermined number of genes as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent;(ii) the agent causes a difference in gene expression below a predetermined number of tissue-specific genes of a tissue as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent; or(iii) the agent causes a difference in gene expression below a predetermined number of genes involved in fetal development as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent.

A method of ascertaining the bio-safety of an agent is disclosed. The method comprises:(a) contacting the agent with differentiating human pluripotent stem cells;(b) analyzing a level of gene expression of a plurality of genes in the differentiating human pluripotent stem cells, wherein the agent is qualified as being safe if at least one of the following qualification parameters are fulfilled:(i) the agent causes a difference in the level of gene expression below a predetermined number of genes as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent;(ii) the agent causes a difference in gene expression below a predetermined number of tissue-specific genes of a tissue as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent; or(iii) the agent causes a difference in gene expression below a predetermined number of genes involved in fetal development as compared to control differentiating human pluripotent stem cells that have not been contacted with the agent.

The invention discloses a method for constructing and analyzing a tissue-specific interaction topology network. The method comprises the following steps of: measuring similarity of integrated interaction network nodes; constructing a tissue-specific gene interaction network, a tissue-specific transcription factor interaction network and a tissue-specific encoded protein interaction network by a construction module of the tissue-specific interaction network; counting connection degree of each node in the network, counting betweenness of each node in the network, calculating closeness of each node in the network, calculating max clique in the interaction network and counting a Hub node in the interaction network by a topology analysis module of the interaction network; and acquiring related tissue-specific knowledge from a gene ontology database and a KEGG (Kyoto Encyclopedia of Genes and Genomes) biological field knowledge base by an identification module of the tissue-specific functional module. The invention provides an ideal method for constructing the interaction network from genetic information; and the method is a more ideal analysis tool for researching a tissue-specific intrinsic mechanism.

The invention discloses a tissue-specific gene and regulatory factor data storage method. In the method, data storage is realized by establishing a tissue-specific gene and regulatory factor database comprising a tissue bank, a gene bank, a gene reference name bank, a tissue-specific gene bank and the tissue bank of tissue-specific genes. The method comprises the following steps of: extracting the tissue-specific genes from a Pubmed bibliographic database in a literature mining form; adding extracted tissue information into the tissue bank; retrieving information about the genes in the European Molecular Biology Laboratory (EMBL), Genebank and NCBI by utilizing names of the genes, and adding the information into corresponding items of the gene bank; and generating regulatory factor XML files by utilizing the information of regulating the searching of the genes from Transfac, an Eukaryotic Promoter Database (EPD) and a compel database. Compared with the prior art, the method has the advantages of bringing convenience to researchers utilizing modern computing technology to detect gene expression and regulate an inherent mechanism of network tissue specificity to acquire data on sequences of the tissue-specific genes and corresponding regulatory factors, fully utilizing tissue-specific gene analysis tools and improving research quality and efficiency.

The invention discloses a TCTP gene space-time specificity conditional and tissue specific gene knock-down animal model construction kit based on a recombinase recognition system, a targeting vector and a construction method thereof of the targeting vector, a mouse TCTP gene specific gene knock-down animal model and a sperm thereof, an oocyte thereof, an oosperm thereof, an embryo thereof, a filial generation thereof, a tissue thereof or a cell thereof as well as applications of the products and methods in an immunology research, researches of immunotoxicology, immunological rejection and andmechanisms thereof, researches of cancer cell apoptosis mechanisms and cancer targets, a research of targeted cancer therapy, safety evaluation, a purpose in the pharmacodynamic evaluation aspect, making of a tumor pathological model and a preparation of a disease treating medicine. By using a homologous recombination technology and an embryonic stem cell technology, a stably genetic TCTP gene knockout mouse is constructed; and therefore, embryonic death caused by knockout of the gene is avoided; and important significance in researches of the TCTP gene in cancer occurrence, progression and treatment are realized.

A method of diagnosing the presence or predicting the course of breast cancer by measuring the expression of a combination of Marker genes comprising a tissue-specific gene and a non-tissue specific gene in a cell or tissue sample derived from a patient. In one aspect of the invention, the genes are mammaglobin and CK19. Kits, nucleic acid primers and probes and controls are provided.

The invention discloses a meta search method for a gene tissue-specific sequence pattern and a search result assessment method and belongs to the field of biological information science. The search method comprises the following steps: extracting promoter sequences of tissue-specific genes and housekeeping (HK) genes from a bioinformatics database as input initial data; carrying out local a search algorithm and an exhaustive search algorithm on the input initial data respectively; storing result tissue generated from the operation of the two search algorithms into a filter matrix; estimating the pattern probability by utilizing the data in the filter matrix; and merging the motifs. In the assessment method, Bayes factor analysis evaluation statistics are utilized to obtain the significance of the search result of the gene tissue-specific motifs. Compared with prior art, the methods provided by the invention have the advantages that the pattern search frame used in the invention integrates multiple algorithms, the principle of 'average result overcomes single choice' which prevails in bioinformatics is conformed, the robustness and creditability of results are improved, the creditability of search results is increased, and over estimation and low estimation of the pattern are avoided.

A method is provided for probabilistically assigning a tissue of origin to a nucleic acid in a sample, e.g., DNA in a cell-free fluid sample obtained from a human subject. A hydroxymethylation profile is generated for the sample DNA and then compared across a reference data set of hydroxymethylation profile vectors, where each hydroxymethylation profile vector identifies the hydroxymethylation profile at a specific reference locus, the tissue-specific gene associated with the reference locus, and the tissue with which the gene and reference locus are associated. A tissue of origin can be probabilistically assigned to the sample nucleic acid using the results of the comparison. Other methods of use are also provided.

Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.

The invention provides an expression vector for a gene therapy, which contains a new combination of transcriptional regulatory elements. The expression vector for the gene therapy comprises a promoter, an enhancer, an untranslated region (UTR), and a locus control region (LCR). The expression vector is capable of continuously expressing in liver tissue-specific genes, thus the expression vector can be effectively used for treating thrombosis, hemophilia, liver cancer, and the like.

Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.

The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca2+]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.

Provided is an expression vector for gene therapy. The expression vector comprises a new combination which contains a transcriptional control element and comprises a promoter, an enhancer, an intron, an untranslated region (UTR) and a loca control region (LCP). The expression vector can continuously express specific genes of hepatic tissue so that the expression vector can be effectively used in treating thrombus forming, hemophilia, liver cancer and the like.

The invention provides an expression vector for gene therapy. The expression vector contains new combination of transcription regulation elements, and comprises a promoter, an enhancer, an intron, a UTR (untranslated region) and an LCR (locus control region). The expression vector can express specific genes of liver tissue continually, thus being applicable to treatment on thrombosis, hemophilia,liver cancer and the like effectively.

The invention provides preparation of human nasopharyngeal tissue-specific gene C10RF102 coded protein and an antibody thereof. The invention adopts polymerase chain reaction to clone a protein-coding sequence of a C10RF102 gene, constructs fusion expression plasmid of the gene, introduces the fusion expression plasmid into RosettaBlue (DE3) escherichia coli, induces and purifies C10RF102 protein, and prepares a monoclonal antibody and a polyclonal antibody; and a C10RF102 gene coded product is specifically expressed in human nasopharyngeal tissue and is in down-regulated expression of nasopharyngeal carcinoma. The preparation of the C10RF102 gene coded product and the antibody thereof can provide a novel means for the gene diagnosis and treatment of the nasopharyngeal carcinoma, and can realize the early diagnosis, early detection and early treatment of the nasopharyngeal carcinoma.

The invention provides application of a ring finger protein Rnf20 gene. By using a Cre-loxp system, an adipose tissue specific Rnf20 gene knockout mouse model is successfully prepared through mating of an Rnf20Flox / Flox mouse and an Adiponectin-Cre + mouse. Adipose specific Rnf20 gene knockout mice (Rnf20Fox / Fox; Adipectin-Cre +) and the control mice (Rnf20Flox / Flox) were used as experimental subjects to study the function of the Rnf20 gene in fat metabolism through animal models induced by age and high fat diet. The results show that compared with thecontrol mice, the adipose-specific Rnf20 gene knockout mice has lipid metabolism disorders that could mimic the pathogenesis of human lipodystrophy. The model is an ideal model for researching lipodystrophy, and has important application value.

The invention discloses an oil content gene locus specific to a tissue part of a rapeseed and application thereof, and belongs to the technical field of molecular biology and genetic breeding. A probelabel sequence closely linked to the oil content gene locus of the outer cotyledon of the rapeseed is as shown by SEQ ID No: 1 or SEQ ID No: 2, a probe label sequence closely linked to the inner cotyledon oil content gene locus is as shown by SEQ ID No: 3 or SEQ ID No: 4, a primer sequence closely linked to the the oil content gene locus of a seed coat is as shown by SEQ ID No: 5 and SEQ ID No: 6, and a primer sequence closely linked to the hypocotyl oil content gene locus is as shown by SEQ ID No: 7. These tissue-specific gene loci provide new loci for improving the oil content of rapeseed by molecular-assisted breeding.

The invention provides an expression vector for a gene therapy, which contains a new combination of transcriptional regulatory elements. The expression vector for the gene therapy comprises a promoter, an enhancer, an untranslated region (UTR), and a locus control region (LCR). The expression vector is capable of continuously expressing in liver tissue-specific genes, thus the expression vector can be effectively used for treating thrombosis, hemophilia, liver cancer, and the like.

The invention discloses an application of LEPTO1 protein and the encoded gene thereof in regulating and controlling male fertility of plants. The present invention provides the use of a substance which inhibits the activity and / or level of LEPTO1 protein in the cultivation of male sterile plants, or a substance for inhibiting or reducing the expression of the LEPTO1 protein coding gene in the cultivation of male sterile plants. The inventors of the present invention apply a genetic editing technology to knock out the CRISPR-Cas9 gene in wild-type rice, which causes the development of pollen mother cells to stagnate in the pre-filament line stage and lead to chromosome degradation and final pollen abortion. The site-specific mutation LEPTO1 protein coding gene can be used for rice fertilitycontrol and hybrid seed production in combination with a tissue-specific gene knock-out technology, so that the method has important significance in rice breeding and can provide important biologicalresources for increasing rice yield and improving rice quality.

The present invention relates to screening the expression patterns of growth-specific genes of pigs and functional cDNA chips using these genes, and provides the nucleotide sequences of new growth factors related to growth in pig muscle and adipose tissue. At the same time, the present invention provides a functional cDNA chip for screening and functional analysis of growth-specific genes according to pig breeds and tissues. integrated in it. Therefore, the functional cDNA chip for screening and functional analysis of growth-specific genes according to pig breeds and tissues can be used to improve pig quality and breed new breeds.

Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.

Provided is an expression vector for gene therapy having a novel combination of transcriptional regulatory elements, including a promoter, an enhancer, an intron, an untranslated region (UTR) and a locus control region (LCR). The expression vector enables sustained expression of a liver tissue-specific gene, and thus, can be effectively used for treating thrombosis, hemophilia, liver cancer, etc.

The invention provides a method for preparing flox rats for PS1 gene conditional knockout. According to the method, a conditional gene knockout carrier is built by adding Cre recombinant enzyme targeting sequence loxP loci at the two ends of a PS1 gene key exon, then a micro-injection method is conducted, and the flox rats capable of being used for PS1 gene conditional knockout are prepared. After the flox rats and Cre rats are mated, PS1 gene knockout rats with tissue specificity or inductive tissue specificity can be obtained. The conditional gene knockout method based on the CRISPR / Cas9 technology can reduce harm to other cells, and specific gene knockout can be achieved only with the need of Cre tool rats. The PS1 gene conditional knockout rats can also serve as anima models for researching the Alzheimer's disease and other diseases, and the method has important and high application value in the aspect of research of functions of the PS1 gene, particularly research of functions of the PS1 gene in nervous tissue.